- organizations:Ocular Therapeutix
Business
Ocular Therapeutix announces executive chairman as new CEO
Effective immediately, Pravin U. Dugel, MD, will also take over as president.Pipeline
FDA amends SPA for Ocular Therapeutix phase 3 wet AMD trial
Modification allows the company to accelerate the enrollment process for the SOL trial.Pipeline
Ocular Therapeutix initiates first pivotal trial of implant for wet AMD
OTX-TKI offers the potential for long-term durability with fewer injections.Research
Enrollment completed for Ocular Therapeutix's HELIOS trial in DR
OTX-TKI has the potential to offer long-term durability and a reduced need for frequent, invasive injections.Pipeline
Ocular Therapeutix releases 12-month topline data from phase 1 wet AMD trial
Efficacy of OTX-TKI could potentially extend beyond three to four months with a single injection.Pipeline